Reference |
4756
Matzkin H, Rangel MC, Soloway MS.
In vitro study of the effect of hyperthermia on normal bladder cell line and on five different transitional cell carcinoma cell lines.
J Urol
1992
147(6):1671-4
PubMed ID: 1593718
DOI: 10.1016/s0022-5347(17)37675-9
|
4755
Brausi M1, Blatnik A, Soloway MS.
Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
Urology
1990
35(3):253-6
PubMed ID: 2316090
DOI: 10.1016/0090-4295(90)80044-n
|
4754
Hickey DP1, Brausi M, Blatnik AF, Soloway MS.
Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Urology
1987
30(5):484-7
PubMed ID: 3118551
DOI: 10.1016/0090-4295(87)90388-8
|
4753
Niell HB, Herrod HG, Blatnik AF, Soloway MS.
In vitro and in vivo activity of two second generation platinum analogs in murine bladder cancer.
J Urol
1985
134(2):399-402
PubMed ID: 3894702
DOI: 10.1016/s0022-5347(17)47186-2
|
4752
Nag S, Blatnik A, Soloway M.
Enhancement of high intensity Iodine-125 brachytherapy by cis-platinum in a murine bladder tumor model.
J Urol
1984
131(6):1225-8
PubMed ID: 6539386
DOI: 10.1016/s0022-5347(17)50877-0
|
4751
Crabtree WN, Soloway MS, Matheny RB Jr, Murphy WM.
Metastatic characteristics of four FANFT-induced murine bladder tumors.
Urology
1983
22(5):529-31
PubMed ID: 6649210
DOI: 10.1016/0090-4295(83)90235-2
|
4750
Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS.
In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.
J Urol
1982
127(6):1233-7
PubMed ID: 7087044
DOI: 10.1016/s0022-5347(17)54305-0
|
1443
Soloway, M S
Intravesical and systemic chemotherapy of murine bladder cancer.
Cancer Res
1977
37:2918-29
PubMed ID: 406041
|
User's Publication |
21762
Suzuki T, Uchida H.
Induction of necroptosis in multinucleated giant cells induced by conditionally replicating syncytial oHSV in co-cultures of cancer cells and non-cancerous cells.
Mol Ther Oncol
2024
32(2):200803
PubMed ID: 38706990
DOI: 10.1016/j.omton.2024.200803
|
18234
Georgiev P, Muise ES, Linn DE, Hinton MC, Wang Y, Cai M, Cadzow L, Wilson DC, Sukumar S, Caniga M, Chen L, Xiao H, Yearley JH, Sriram V, Nebozhyn M, Sathe M, Blumenschein WM, Kerr KS, Hirsch HA, Javaid S, Olow AK, Moy LY, Chiang DY, Loboda A, Cristescu R, Sadekova S, Long BJ, McClanahan TK, Pinheiro EM.
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
Mol Cancer Ther
2022
21(3):427-439
PubMed ID: 34965960
DOI: 10.1158/1535-7163.MCT-21-0561
|
13186
Huetter J, Gritzan U, Gutcher I, Doecke WD, Luetke-Eversloh MV, Golfier S, Roider HG, Frisk AL, Hunter J, Pow A, Drake A, Levine Z, Levy O, Azulay M, Barbiro I, Cojocaru G, Vaknin I, Kreft B, Roese L.
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).
Cancer Immunol Res
2020
PubMed ID: 32312711
DOI: 10.1158/2326-6066.CIR-19-0321
|
11603
Aoki N, Matsui Y.
Comprehensive Analysis of Mouse Cancer/Testis Antigen Functions in Cancer Cells and Roles of TEKT5 in Cancer Cells and Testicular Germ Cells.
Mol. Cell. Biol.
2019
PubMed ID: 31208979
DOI: 10.1128/MCB.00154-19
|
14361
Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC
J Thorac Oncol
2019
14(12):2152-2163
PubMed ID: 31470128
DOI: 10.1016/j.jtho.2019.08.009
|
7121
Kato S, Mori S, Kodama T.
A Novel Treatment Method for Lymph Node Metastasis Using a Lymphatic Drug Delivery System with Nano/Microbubbles and Ultrasound.
J Cancer
2015
6:1282-94
PubMed ID: 26640589
DOI: 10.7150/jca.13028
|
18170
Takagi S, Oh-hara T, Sato S, Gong B, Takami M, Fujita N.
Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis
Int J Cancer
2014
134(11):2605-14.
PubMed ID: 24222607
DOI: 10.1002/ijc.28602
|
15665
Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H.
Nanoparticulation of BCG-CWS for application to bladder cancer therapy
J Control Release
2014
176:44-53
PubMed ID: 24389133
DOI: 10.1016/j.jconrel.2013.12.027
|
8207
Kaori Yoshino, Kaoru Saijo, Chikako Noro and Yukio Nakamura
Development of a simple method to determine the mouse strain from which cultured cell lines originated
Interdisciplinary Bio Central
2010
2:0014
DOI: 10.4051/ibc.2010.2.4.0014
|
8911
FAN You-ming, GAO Yu-qi, HUANG Jian, LIAO Wei-gong, CAI Ming-chun
Screening and identification of differentially expressed genes in hippocampus of mice during hypobaric hypoxic delayed preconditioning
Chinese Journal of Pathophysiology
2006
22:342-346
|
9046
Shin-ichi Kohno 1, Chenhong Luo, Fumi Goshima, Yukihiro Nishiyama, Tetsutaro Sata, Yoshinari Ono
Herpes Simplex Virus Type 1 Mutant HF10 Oncolytic Viral Therapy for Bladder Cancer
Urology
2005
66 (5), 1116-21
PubMed ID: 16286150
DOI: 10.1016/j.urology.2005.05.041
|
17468
Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y.
Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer
Med Electron Microsc
2004
;37(4):216-24
PubMed ID: 15614446
DOI: 10.1007/s00795-004-0247-2
|
2669
Shibata MA, Horiguchi T, Morimoto J, Otsuki Y
Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer.
J Gene Med
2003
5:219-31
PubMed ID: 12666188
DOI: 10.1002/jgm.335
|